Oxiquim S.A (OXIQUIM) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Oxiquim S.A CLP 12,262, price CLP 13,100, upside -6.4%, quality 62 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Oxiquim S.A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 750.52 CLP – 13,100 CLP · fair‑value band 7,788 CLP – 17,374 CLP · the 13,100 CLP price screens above the 12,262 CLP fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Oxiquim in your weekly email
Every Wednesday you see whether Oxiquim is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Oxiquim S.A. engages in the production and sale of resins for the wood board industry in Chile.
Show more
Oxiquim S.A. engages in the production and sale of resins for the wood board industry in Chile. It offers liquid petroleum gas, clean fuels, wood board, animal feed and nutrition, human food, food flexible packaging films, thermoplastic and compostable resins, paints, coating, and adhesives; industrial water, desalination, purification and treatment; pharmaceuticals and cosmetics, mining, detergents and cleaning, cellulose and paper, HPLC solvents and ACS reagents, and other products. The company also provides reception, storage, and dispatch services for liquid bulk, serving mining companies, LPG and fuel distributors, pulp mills, paint and coating manufacturers, and resins and adhesive producers. In addition, it is involved in the distribution and marketing of a range of chemicals, raw materials, and specialties for the productive industry; and marketing, sales and technical support, product development, supply chain and logistics, sourcing and procurement, mixing and formulation, packaging and drumming, and private labeling services. The company was founded in 1955 and is based in Santiago, Chile.
Stock analysis
Oxiquim S.A (OXIQUIM) currently trades at 13,100 CLP, while our model-based Fair Value estimate is 12,262 CLP, implying the stock looks roughly 6.8% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 16,242 CLP per share, and 12 of the 24 models we run sit above the 13,100 CLP price.
Bear case: the Asset-Based group reads lowest at 3,292 CLP, and 12 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 7,788 CLP (bear) to 17,374 CLP (bull), the price of 13,100 CLP sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Oxiquim S.A reported revenue of 237B CLP in FY2025 versus 191B CLP in FY2021, a compound +5.5%/yr. Reported net income was 26.1B CLP in FY2025, compounding +6.0%/yr from FY2021.
Key figures
Market cap 326B CLP (≈ $339M) · P/S ratio 1.31 · EPS (TTM) 1.24 CLP · Dividend yield 8.3% · Net margin 11.0% · Return on equity 19.0% · Return on assets (EBIT) 14.0% · Operating margin 12.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 20% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −27% fair-value upside, at −6%, OXIQUIM screens cheaper than that median.
Fair Value models
Bear 7,788 CLPFair Value 12,262 CLPBull 17,374 CLP
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+0.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Start year 2020 (pandemic). Over 10 years: +5.1% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
’14
’15
’16
’17
’18
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in CLP ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in CLP: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+14.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.6%
Dividend (yield on the price)8.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 13%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Chile: IMF forecast 3.0% a year to 2030, 4.5% from 2016 to 2025) that is about +10.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Chemicals · 352 stocks
Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score62 · Top 25%
Fair Value upside−6% · Above median
Profitability
Return on equity (TTM)19% · Top 25%
Return on assets7% · Top 25%
Net margin (TTM)10% · Top 25%
Operating margin (TTM)12% · Above median
Growth and dividend
Revenue growth−15% · Bottom 25%
Dividend yield (TTM)8.3% · Top 25%
Balance sheet
Debt / equity0.24× · Above median
Valuation Multiplesvs Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Oxiquim S.A Fair Value". https://www.fairvalue-calculator.com/stock/OXIQUIM
Frequently asked questions
Is Oxiquim S.A (OXIQUIM) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 12,262 CLP versus a price of 13,100 CLP, about −6% upside (fairly valued).
What is the fair value of OXIQUIM?
Our model-based fair value for Oxiquim S.A is 12,262 CLP (as of Sep 24, 2026), built from audited fundamentals. The current price: 13,100 CLP.
What is the quality score of OXIQUIM?
Oxiquim S.A has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oxiquim S.A (OXIQUIM)?
Our model-based price target is the fair value of 12,262 CLP (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 7,788 CLP, optimistic scenario 17,374 CLP. It is a calculation from audited fundamentals, not an analyst target.
What is the Oxiquim S.A stock forecast for 2026?
Our models put fair value at 12,262 CLP, about −6% upside versus a price of 13,100 CLP (fairly valued). Cautious scenario 7,788 CLP, optimistic scenario 17,374 CLP. The calculation is refreshed regularly with new filings.
What is the revenue of Oxiquim S.A (OXIQUIM)?
Oxiquim S.A reported trailing-twelve-month revenue of about 228B CLP (latest available figure, as of Sep 24, 2026).
Does Oxiquim S.A pay a dividend?
Oxiquim S.A currently shows a dividend yield of about 8.28% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Oxiquim S.A (OXIQUIM)?
For today's price to be fair in a discounted-cash-flow model, Oxiquim S.A would have to grow free cash flow by +14.3 % per year for five years (discount rate 13.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of OXIQUIM use?
Our models discount Oxiquim S.A at 13.6 %: a base by market capitalisation (micro), country premium for Chile. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Oxiquim S.A that is +14.3 % per year a year over ten years, using the same discount rate (13.6 %) and the same formula as our fair value.
How much growth has Oxiquim S.A (OXIQUIM) delivered so far?
Over the past 5 years revenue at Oxiquim S.A grew +8.4 % a year. The price currently implies +14.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Oxiquim S.A (OXIQUIM) growing?
The median revenue growth in the sector is +3.3 % a year. That is the yardstick for the growth priced into Oxiquim S.A (+14.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Oxiquim S.A (OXIQUIM)?
The free-cash-flow yield on the price is 7.04 %: that much free cash flow Oxiquim S.A produces per unit of market value. When it exceeds the discount rate of our models (13.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Oxiquim S.A (OXIQUIM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oxiquim S.A it is 12,262 CLP per share (as of Sep 24, 2026), against a price of 13,100 CLP. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Oxiquim S.A stock overvalued or undervalued in 2026?
As of Sep 24, 2026, OXIQUIM trades above its calculated fair value: price 13,100 CLP, fair value 12,262 CLP, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OXIQUIM?
No. The price is what the market pays today (13,100 CLP); the fair value is what the company's own numbers justify (12,262 CLP). For Oxiquim S.A the two are 838.21 CLP per share apart. That gap is exactly why we show both numbers side by side.
How much is Oxiquim S.A worth?
The market values Oxiquim S.A at about 326B CLP (market capitalisation, as of Sep 24, 2026). Per share that is 13,100 CLP; our models calculate a fair value of 12,262 CLP per share.
What do the bullish and bearish scenarios say about OXIQUIM?
Our models span a range for Oxiquim S.A: cautious scenario 7,788 CLP, base 12,262 CLP, optimistic 17,374 CLP per share (as of Sep 24, 2026, price 13,100 CLP). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oxiquim S.A (OXIQUIM)?
Balance-sheet figures for Oxiquim S.A (as of Sep 24, 2026): return on equity 19.0%, debt of 0.24 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is OXIQUIM from its 52-week high?
Oxiquim S.A trades at 13,100 CLP, at its 52-week high of 13,100 CLP and 20% above the low of 10,912 CLP (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 12,262 CLP is for.
Which stocks are comparable to Oxiquim S.A?
From the same area (Basic Materials) we also value BASF SE, Saudi Basic Industries Corporation, Ningxia Baofeng Energy Group, Dow Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oxiquim S.A stock attractive at the current price?
The data as of Sep 24, 2026: price 13,100 CLP, calculated fair value 12,262 CLP (−6%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OXIQUIM calculated?
We run Oxiquim S.A through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 12,262 CLP, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Oxiquim S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oxiquim S.A (OXIQUIM)?
The closing price on Sep 23, 2026 was 13,100 CLP. Our model-based fair value is 12,262 CLP, about −6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oxiquim S.A right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (7,788 CLP to 17,374 CLP) leaves room in how you read the outcome.
Key figures of Oxiquim S.A
How large is the market capitalisation of Oxiquim S.A (OXIQUIM)?
The market capitalisation of Oxiquim S.A is 326B CLP (≈ $339M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oxiquim S.A (OXIQUIM)?
The price-to-sales ratio of Oxiquim S.A is 1.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oxiquim S.A (OXIQUIM)?
Earnings per share at Oxiquim S.A are 1.24 CLP. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Oxiquim S.A (OXIQUIM)?
The dividend yield of Oxiquim S.A is 8.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Oxiquim S.A (OXIQUIM)?
The net margin of Oxiquim S.A is 11.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oxiquim S.A (OXIQUIM)?
The return on equity (ROE) of Oxiquim S.A is 19.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oxiquim S.A (OXIQUIM)?
On an EBIT basis the return on assets of Oxiquim S.A is 14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oxiquim S.A (OXIQUIM)?
The operating margin of Oxiquim S.A is 12.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oxiquim S.A (OXIQUIM)?
Revenue at Oxiquim S.A is growing −14.6% versus a year earlier (3y avg −3.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oxiquim S.A (OXIQUIM)?
Earnings per share at Oxiquim S.A are growing −34.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Oxiquim S.A (OXIQUIM) carry?
The net debt of Oxiquim S.A is 47.1B CLP (fiscal year 2025, ≈ 2.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Oxiquim S.A in the live analysis
One click puts Oxiquim S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
